RxDoctor Payments Data

Theodore Frank, MD

Cardiovascular Disease · Charlotte, NCNPI 1942211164

Payments from drug & device makers

$77,683in general payments, 2019–2025

Across 110 payments — averaging $706.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$27K
  • United Therapeutics Corporation$24K
  • AstraZeneca$10K
  • Kestra Medical Technology Services, Inc.$10K
  • Merck$4K
  • Abiomed$1K
  • plus $2K from 11 others

What the payments were for

  • Consulting fees$28,88057%
  • Speaking & faculty fees$14,38028%
  • Travel & lodging$3,2046%
  • Food & beverage$4,0078%
  • Education$1390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,683 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$72,848
Medicare patients
258
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan270$3,405,854
Tyvaso DpiTreprostinil89$2,137,984
AdempasRiociguat86$1,201,444
UptraviSelexipag31$985,556
WinrevairSotatercept-Csrk45$771,852
Ambrisentan181$449,914
LetairisAmbrisentan29$368,539
Orenitram ErTreprostinil Diolamine27$284,083
EntrestoSacubitril/Valsartan207$243,271
JardianceEmpagliflozin213$221,806
EliquisApixaban114$109,044
FarxigaDapagliflozin Propanediol89$78,215
AdcircaTadalafil11$75,956
Tadalafil96$69,543
XareltoRivaroxaban27$24,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$304$4,391,410301 claims
MerckWinrevair$3,643$771,85245 claims
NovartisEntresto$58$243,271207 claims
PfizerEliquis$15$109,044114 claims
AstraZenecaFarxiga$10,468$78,21589 claims
United Therapeutics CorporationAdcirca$24,143$75,95611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →